Management of chronic hepatitis B

Journal of Hepatology, Supplement

Volumn 38, Issue 1, 2003, Pages

  Conjeevaram, Hari S ^a   Lok, Anna Suk Fong ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA2A INTERFERON; CLEVUDINE; DEOXYADENOSINE; DEOXYCYTIDINE; EMTRICITABINE; ENTECAVIR; FAMCICLOVIR; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; MACROGOL; PREDNISONE; RIBAVIRIN; THYMIDINE; VIRUS DNA; CORTICOSTEROID; DNA; HEPATITIS B ANTIGEN; HEPATITIS B SURFACE ANTIGEN; PEGINTERFERON;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANXIETY DISORDER; BIOLOGICAL MONITORING; BONE MARROW SUPPRESSION; CHRONIC HEPATITIS; CLINICAL TRIAL; DEPRESSION; DISEASE COURSE; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FLU LIKE SYNDROME; GENOTYPE; HAIR LOSS; HEPATITIS B; HEPATITIS B VIRUS; HISTORY OF MEDICINE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IMMUNOMODULATION; IRRITABILITY; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER DISEASE; META ANALYSIS; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VIRUS REPLICATION; WEIGHT REDUCTION; ANTIVIRAL ACTIVITY; ANXIETY NEUROSIS; CORTICOSTEROID THERAPY; DNA DETERMINATION; DRUG DOSE REGIMEN; GEOGRAPHIC DISTRIBUTION; LIVER CARCINOGENESIS; LIVER FIBROSIS; MENTAL INSTABILITY; SEROCONVERSION; SUICIDE ATTEMPT; VIRUS INACTIVATION;

ANTIVIRAL AGENTS; HEPATITIS B, CHRONIC; HUMANS; INTERFERONS;

EID: 0037223033     PISSN: 01695185     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733.
2. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000-summary of a workshop. Gastroenterology 2001;120:1828.
3. Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001;120:1009.
4. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Taiwan community-based cancer screening project group. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168.
5. Realdi G, Fattovich G, Hadziyannis S, Schalm SW, Almasio P, Sanchez-Tapias J, Christensen E, Giustina G, Noventa F. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1994;21:656.
6. Kidd-Ljunggren K, Miyakawa Y, Kidd AH. Genetic variability in hepatitis B viruses. J Gen Virol 2002;83:1267.
7. Chu CJ, Lok AS. Clinical significance of hepatitis B virus genotypes. Hepatology 2002;35:1274.
8. Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002;122:1756.
9. Kao JH, Chen PJ, Lai MY, Chen DS, Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. J Clin Microbiol 2002;40:1207.
10. Kao JH, Wu NH, Chert PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000;33:998.
11. Zhang X, Zoulim F, Habersetzer F, Xiong S, Trepo C. Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B. J Med Virol 1996;48:8.
12. Zollner B, Petersen J, Schafer P, Schroter M, Laufs R, Sterneck M, et al. Subtype-dependent response of hepatitis B virus during the early phase of lamivudine treatment. Clin Infect Dis 2002;34:1273.
13. Hunt CM, McGill JM, Allen MI, Condreay LD. Clinical relevance of hepatitis B viral mutations. Hepatology 2000;31:1037.
14. Okamoto H, Tsuda F, Akahane Y, Sugai Y, Yoshiba M, Moriyama K, Tanaka T, Miyakawa Y, Mayumi M. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 1994;68:8102.
15. Miyakawa Y, Okamoto H, Mayumi M. The molecular basis of hepatitis B e antigen (HBeAg)-negative infections. J Viral Hepat 1997;4:1.
16. Lok AS, Akarca US, Greene S. Predictive value of precore hepatitis B virus mutations in spontaneous and interferon-induced hepatitis B e antigen clearance. Hepatology 1995;21:19.
17. Erhardt A, Reineke U, Blondin D, Gerlich WH, Adams O, Heintges T, Niederau C, Haussinger D. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology 2000;31:716.
18. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119(4):312.
19. Craxi, A, Bona, DD, Camma, C. Interferon alpha for HBeAg positive chronic hepatitis B: systematic review. Proceedings of EASL International Consensus Conference on Hepatitis B, 2002.
20. Bortolotti F, Jara P, Barbera C, Gregorio GV, Vegnente A, Zancan L, Hierro L, Crivellaro C, Vergani GM, Iorio R, Pace M, Con P, Gatta A. Long term effect of alpha interferon in children with chronic hepatitis B. Gut 2000;46:715.
21. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422.
22. Sokal EM, Conjeevaram HS, Roberts EA, Alvarez F, Bern EM, Goyens P, Rosenthal P, Lachaux A, Shelton M, Sarles J, Hoofnagle J. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 1998;114:988.
23. Fattovich G, Giustina G, Sanchez-Tapias J, Quero C, Mas A, Olivotto PG, Solinas A, Almasio P, Hadziyannis S, Degos F, de Moura MC, Krogsgaard K, Pantalena M, Realdi G, Corrocher R, Schalm SW. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP). Am J Gastroenterol 1998;93:896.
24. Lau DT, Everhart J, Klainer DE, Park Y, Vergalla J, Schmid P, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997;113:1660.
25. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999;29:971.
26. Lok AS, Chung HT, Liu VW, Ma OC. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 1993;105:1833.
27. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001;34:306.
28. Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002;36:263.
29. Janssen HL, Schalm SW, Berk L, de Man RA, Heijtink RA. Repeated courses of alpha-interferon for treatment of chronic hepatitis type B. J Hepatol 1993;17(Suppl. 3):S47.
30. Carreno V, Marcellin P, Hadziyannis S, Salmeron J, Diago M, Kitis GE, Vafiadis I, Schalm SW, Zahm F, Manzarbeitia F, Jimenez FJ, Quiroga JA. Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1999;30:277.
31. Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001;121:101.
32. Hoofnagle JH, Di Bisceglie AM, Waggoner JG, Park Y. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993;104:1116.
33. Perrillo R, Tamburro C, Regenstein F, Balart L, Bodenheimer H, Silva M, Schiff E, Bodicky C, Miller B, Denham C, Brodeur C, Roach K, Albrecht J. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995;109:908.
34. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997;30:336-347.
35. Cohard M, Poynard T, Mathurin P, Zarski JP. Prednisone-interferon combination in the treatment of chronic hepatitis B: direct and indirect meta-analysis. Hepatology 1994;20:1390.
36. Mellerup MT, Krogsgaard K, Mathurin P, Gluud C, Poynard T. Sequential combination of gucocorticosteroids and alfa interferon versus alfa interferon alone for HBeAg-positive chronic hepatitis B (Cochrane review). In: The Cochrane library, Issue 3, 2002.
37. Cooksley WGE, Piratvisuth T, Wang YJ, Mahacchai V, Chao Y-C, Tanwandee T, Chutaputti A, Chang WY, Zahm FE, Pluck N. 40 KDA Peginterferon alfa-2A (Pegasys): Efficacy and safety results from phase II, randomized, actively controlled, multicenter study in the treatment of HBeAg positive chronic hepatitis B (abstract). Hepatology 2001;34:349A.
38. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001;34:1225.
39. Janssen HL, Gerken G, Carreno V, Marcellin P, Naoumov NV, Craxi A, Ring-Larsen H, Kitis G, van Hattum J, de Vries RA, Michielsen PP, ten Kate FJ, Hop WC, Heijtink RA, Honkoop P, Schalm SW. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1999;30:238.
40. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61.
41. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256.
42. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomized trial. Gut 2000;46:562.
43. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, Lai CL. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000;119:172.
44. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RN. On behalf of the Asia Hepatitis Lamivudine Study Group. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 2001;33:1527.
45. Guan R, Lai CL, Liaw YF, Lim SG, Lee CM. Efficacy and safety of 5 years lamivudine treatment of Chinese patients with chronic hepatitis B. J (abstract). Gastroenterol Hepatol 2001;16(Suppl. 1):A60 Abstract 187.
46. Jonas MM, Kelly DA, Mizerski J, Badia IB, Areias JA, Schwarz KB, Little NR, Greensmith MJ, Gardner SD, Bell MS, Sokal EM, Kelley DA. International Pediatric Lamivudine Investigator Group. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002;346:1706.
47. Chien RN, Liaw YF, Atkins M, for Asian Hepatitis Lamivudine Trial Group. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999;30:770.
48. Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, Heathcote EJ, Brown NA, Atkins M, Woessner M, Gardner SD. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002;36:186.
49. Rizzetto M. Efficacy of lamivudine in HBeAg-negative chronic hepatitis B. J Med Virol 2002;66:435.
50. Gaia S, Volpes R, Smedile A, Paganin S, Actis GC, Rizzetto M. Lamivudine in anti-HBeAg positive chronic hepatitis B: response after one year of treatment. J Hepatol 2000;32(Suppl. 2): 112.
51. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, Barber J, Condreay L. Gray, D.F. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999;29:889.
52. Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000;32:300.
53. Buti M, Cotrina M, Jardi R, de Castro EC, Rodriguez-Frias F, Sanchez-Avila F, Esteban R. Guardia, J. Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B. J Viral Hepat 2001;8:270.
54. Schiff E, Karayalcin S, Grimm I, Perrillo R, Dienstag J, Husa P, Schalm S, Crowther L, Sullivan M, Woessner M, McPhillips P, Brown N, and the International Lamivudine Investigator Group. A placebo controlled study of lamivudine and interferon alpha 2b in patients with chronic hepatitis B who previously failed interferon therapy (abstract). Hepatology 1998;28:388A.
55. Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, et al. The Lamivudine North American Transplant Group. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001;33:424.
56. Fontana RJ, Keeffe EB, Carey W, Fried M, Reddy R, Kowdley KV, Soldevila-Pico C, McClure LA. Lok AS; for the National Institutes of Health Hepatitis B Virus Orthotopic Liver Transplantation Study Group. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl. 2002;8:433.
57. Fontana RJ, Hann HW, Perrillo RP, Vierling JM, Wright T, Rakela J, Anschuetz G, Davis R, Gardner SD, Brown NA. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002;123:719.
58. Colquhoun SD, Belle SH, Samuel D, Pruett TL, Teperman LW. Transplantation in the hepatitis B patient and current therapies to prevent recurrence. Semin Liver Dis 2000;20(Suppl. 1):7-12.
59. Anselmo DM, Ghobrial RM, Jung LC, Weaver M, Cao C, Saab S, Kunder G, Chen PW, Farmer DG, Yersiz H, Baquerizo A, Geevarghese S, Han SH, Goldstein L, Holt CD, Gornbein JA, Busuttil RW. New era of liver transplantation for hepatitis B: a 17-year single-center experience. Ann Surg 2002;235:611.
60. Perrillo R, Rakela J, Dienstag J, Levy G, Martin P, Wright T, Caldwell S, Schiff E, Gish R, Villeneuve JP, Farr G, Anschuetz G, Crowther L, Brown N. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group. Hepatology 1999;29:1581.
61. Leung NW, Liaw YF, Chang TT, Guan R, Lee C-M, Ng K-Y, Lim S-G, Nicholls GJ, Dent JC. Durable HBeAg response in Chinese patients treated with lamivudine (abstract). Hepatology 2001;34:348A.
62. Song BC, Sub DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32:803.
63. Chien RN, Liaw YF, Tsai SL, Yeh CT, Chu CM. HBV genotype is the major factor for durability of HBeAg responses to lamivudine therapy. Gastroenterol J Taiwan 2002;19:65.
64. Leung N, Lai CL, Liaw Y-F. The effect of longer duration of harbouring lamivudine-resistant hepatitis B virus (YMDD mutants) on liver histology duirng 3 years lamivudine therapy in Chinese patients (abstract). Hepatology 2001;34:348A.
65. Chang TT, Lai CL, Liaw YF, Guan R, Lim SG, Lee CM, Ng KY. Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV (CHB) patients treated with lamivudine for four years. Antiviral Ther 2000;5(Suppl. 1):44.
66. Leung NY, Lai CL, Yao GB, Marr C, Chin J, Atkins M. Long-term safety of lamivudine in asian and Caucasian patients with chronic hepatitis B. J Hepatol 2001;34(Suppl. 1):160.
67. Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000;32:635.
68. Liaw YF, Chien RN, Yeh CT, et al. To continue or not continue lamivudine therapy after emergence of YMDD mutations (abstract). Gastroenterology 2002;122(Suppl. 1):A628.
69. Wong VW, Chan HL, Wong ML, Leung N. Is it safe to stop lamivudine after the emergence of YMDD mutants during lamivudine therapy for chronic hepatitis B? (abstract). J Hepatol 2002;36(Suppl. 1):177.
70. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF. Nomenclature for antiviral-resistant human hepatitis B mutations in the polymerase region. Hepatology 2001;33:751.
71. Liaw Y-F. Results of lamivudine in Asian trials. Proceedings of EASL International Consensus Conference on Hepatitis B, 2002.
72. Kao J-H, Liu C-J, Chen D-S. Hepatitis B viral genotypes and lamivudine resistance. J Hepatol 2002;36:303.
73. Papatheoridis GV, Dimou E, Laras A, Papadimitopoulos V, Hadziyannis S. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002;36:219.
74. Gilson RJ, Chopra KB, Newell AM, Murray-Lyon IM, Nelson MR, Rice SJ, Tedder RS, Toole J, Jaffe HS, Weller IV. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. J Viral Hepatol 1999;6:387.
75. Marcellin P, Chang TT, Lim SG, Sievert W, Tong M, Jain A, James C, Chen S, Fry J, Brosgart C. Adefovir diopivoxil (ADV) 10 mg for the treatment of patient with HBeAg + chronic hepatitis B: continued efficacy beyond 48 weeks. Hepatology 2002;36:373A.
76. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman M, Jeffers L, Goodman Z, Ma J, Jain A, Fry J, Brosgart CL. GS-98-437 A double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for the treatment of patients with HBeAg + chronic hepatitis B infection: 48 week results (abstract). Hepatology 2001;34:340A.
77. Marcellin P, Goodman Z, Chang TT, Lim SG, Tong M, Sievert W, Shiffman M, Jeffers L, Wufsohn M, Fallis R, Fry J, Brosgart C. Histological improvement in HBeAg positive chronic hepatitis B patients treated with adefovir dipivoxil (abstract). J Hepatol 2002;36(Suppl. 1):8.
78. Hadiziyannis S, Tassopolous N, Heathcote E, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Wulfsohn M, Wollman M, Fry J, Brosgart C. A double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B: 48 week results (abstract). J Hepatol 2002;36(Suppl 1):4.
79. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, Gutfreund K, Lamy P, Murray A. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32:129.
80. Perrillo R, Schiff E, Hann H-W, Buti M, Strasser S, Watkins KM, Moorat AE, Woessner MA, Vig P, Brosgart CL, Bourne EC, Atkins AC. The addition of adefovir dipivoxil to lamivudine in decompensated chronic hepatitis B patients with YMDD variant HBV and reduced response to lamivudine-preliminary 24 week results (abstract). Hepatology 2001:34:349A.
81. Schiff ER, Lai CL, Neuhaus P, Tillmann H, Samuel D, Villenuve JP, Hadziyannis S, Xiong S, Lama N, James C, Fry J, Namini H, van Doren S, Brosgart CL. Adefovir dipivoxil (ADV) for the treatment of chronic hepatitis B in patients pre- and post- liver transplantation (OLT) with lamivudine resistant (LAM-R) hepatitis B virus (HBV) patients (abstract). Hepatology 2002;36:371A.
82. Peters M, Hann HW, Martin P, Heathcote E, Buggisch P, Moorat AE, Sullivan M, Kleber K, Ebrahimi R, Xiong S, Brosgart C. Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses YMDD mutant hepatitis B virus replication: 48 week preliminary analysis (abstract). Hepatology 2002;36:374A.
83. Yang H, Westland CE, Delaney WE 4th, Heathcote EJ, Ho V, Fry J, Brosgart C, Gibbs CS, Miller MD, Xiong S. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002;36:464.
84. de Man RA, Marcellin P, Habal F, Desmond P, Wright T, Rose T, Jurewicz R, Young C. A randomized placebo-controlled study on the efficacy of 12 month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B. Hepatology 2000;32:413.
85. Aye TT, Bartholomeusz A, Shaw T, Bowden S, Breschkin A, McMillan J, Angus P, Locarnini S. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol 1997;26:1148.
86. Trinh H, Lang W, Kessler HA, Fang L, Wang LH, Delehanty J, Rigney A, Mondou E, Snow A, Rousseau F. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother 2002;46:1734.
87. Lamb L, Durham SK, Huang ML, Corey L, Littlejohn M, Locarnini S, Tennant BC, Rose B, Clark JM. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis 2001;184:1236.
88. Tassopoulos N, Hadziyannis S, Cianciara J, Rizzetto M, Schiff ER, Pastore G, Rutkiewicz V, Thomas N, Deniski G, Joshi S. Entecavir is effective in treating patients with chronic hepatitis B who have failed lamivudine therapy (abstract). Hepatology 2001;34:340A.
89. Levine S, Hernandez D, Yamanaka G, Zhang S, Rose R, Weinheimer S, Colonno RJ. Efficacies of entecavir against lamivudine-resistant hepatitis b virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 2002;46:2525.
90. Lai CL, Myers MW, Pow DM, Brown NA, Lee Y-M, Yuen M-F, Lim SG. Safe and potent suppression of hepatitis B virus (HBV) with L-deoxythymidine (LDT): Results of a dose-escalation trial (abstract). Hepatology 2001;34:321A.
91. Zhou X-J, Lim S-G, Lai C-L, Lam P-F, Murphy RL, Pow DM, Myers MW, Phase I. dose escalation pharmacokinetics of with L-deoxythymidine (LDT) in patients with chronic hepatitis B virus (CHB) infection (abstract). Hepatology 2001;34:629A.
92. Peek SF, Cote PJ, Jacob JR, Toshkov IA, Hornbuckle WE, Baldwin BH, Wells FV, Chu CK, Gerin JL, Tennant BC, Korba BE. Andviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax). Hepatology 2001;33:254.
93. Marcellin P, Sereni D, Sacks S, Bronowicki J-P, Sista ND, Fang L, Yoo BC, Rousseau FS, Lee H-S. And-HBV activity and tolerability of clevudine, a novel nucleoside-analogue: Initial results of a phase I/II 28-day study (abstract). Hepatology 2001;34:320A.
94. Barbarini G, Zechini F, Pellicelli A, Spallanzani L, Francavilla R, Scotto G, Bacca D, Bruno M, Babudieri S, Matarazzo F, Annese M, Di Stefano G, Barbaro G. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial (abstract). Hepatology 2001;34:318A.
95. Santantonio T, Niro GA, Sinisi E, Leandro G, Insalata M, Guastadisegni A, Facciorusso D, Gravinese E, Andriulli A, Pastore G. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. J Hepatol Jun; 2002;36:799.
96. Cotonat T, Quiroga JA, Lopez-Alcorocho JM, Clouet R, Pardo M, Manzarbeitia F, Carreno V. Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients. Hepatology 2000;31:502.
97. Lau GK, Tsiang M, Hou J, Yuen S, Carman WF, Zhang L, Gibbs CS, Lam S. Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study. Hepatology 2000;32:394.
98. Chien RN, Liaw YF, Chen TC, Yeh CT, Sheen IS. Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology 1998;27:1383.
99. Mutchnick MG, Lindsay KL, Schiff ER, Cummings GD, Appelman HD, Peleman RR, Silva M, Roach KC, Simmons F, Milstein S, Gordon SC, Ehrinpreis MN. Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicenter, randomized, double-blind and placebo-controlled study. J Viral Hepatitis 1999;6:397.
100. Chan HL, Tang JL, Tam W, Sung JJ. The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. Aliment Pharmacol Ther 2001;15:1899.
101. Lau GK, Suri D, Liang R, Rigopoulou EI, Thomas MG, Mullerova I, Nanji A, Yuen ST, Williams R, Naoumov NV. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 2002;122:614.